https://www.statnews.com/2020/04/29/biogen-spinraza-competition-ridiplam-spinal-muscular-atrophy/?utm_source=STAT+Newsletters&utm_campaign=a124ea3d93-Daily_Recap&utm_medium=email&utm_term=0_8cab1d7961-a124ea3d93-149692869

STAT Plus: Biogen’s blockbuster rare disease drug could be in trouble

By DAMIAN GARDE

SCOTT LAPIERRE/THE BOSTON GLOBE

New data on a spinal muscular atrophy treatment is good news for patients — but could spell trouble for Biogen's competing drug.

READ MORE